APAC In Vivo CAR-T Therapy Market Industry Trends and Forecast to 2034: Segmented by (Delivery, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$17.4 MnPlaceholder estimate
Estimate 2025$26.2 Mn23.3% of the global market
Projected 2034$1.06 Bn 3,957%Adds $1.04 Bn over 9 forecast years
CAGR 2025–203450.9%Faster than 99% of 183 Pharmaceuticals markets here
Key players5Companies profiled
APAC is 23.28% of the global market.
Among regions, the largest is North America at $49.4 Mn.
Capstan Therapeutics (AbbVie), Umoja Biopharma, Interius BioTherapeutics, Kelonia Therapeutics, EsoBiotec (AstraZeneca) (see all)
Active clinical trials
32 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC In Vivo CAR-T Therapy Market Analysis Executive Summary
In vivo CAR-T therapy delivers instructions straight into the body so a patient's own T cells become cancer fighters, without lab manufacturing.
Key segments of the in Vivo CAR-T Therapy market include delivery (Lentiviral Vectors, Lipid Nanoparticles and Targeted Viral Vectors) and indication (Blood Cancers, Autoimmune Diseases and Solid Tumors).
Asia Pacific In Vivo CAR-T Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC In Vivo CAR-T Therapy Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the in Vivo CAR-T Therapy market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the in Vivo CAR-T Therapy market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the in Vivo CAR-T Therapy market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for In Vivo CAR-T Therapy Market in APAC
The in Vivo CAR-T Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for In Vivo CAR-T Therapy Market in APAC
In Vivo CAR-T Therapy in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9], Thai FDA (Thailand)[10], BPOM (Indonesia)[11], DRAP (Pakistan)[12], MFDS (South Korea)[13] and Drug Administration of Vietnam (Vietnam)[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[15], basic medical insurance (China)[16], the Hospital Authority (Hong Kong)[17], Ayushman Bharat PM-JAY (India)[18], public health insurance (Japan)[19], subsidised public care (Malaysia)[20], Pharmac (New Zealand)[21], PhilHealth (Philippines)[22], MediShield Life (Singapore)[23], the Universal Coverage Scheme (Thailand)[24], JKN (BPJS Kesehatan) (Indonesia)[25], out of pocket and Sehat Sahulat (Pakistan)[26], National Health Insurance (South Korea)[27] and social health insurance (Vietnam)[28]. ClinicalTrials.gov lists 32 studies on In Vivo CAR-T Therapy that are recruiting, active or about to start in APAC.[29]
[29]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for in Vivo CAR-T Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Delivery
4.2 By Indication
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Capstan Therapeutics (AbbVie)
7.2 Umoja Biopharma
7.3 Interius BioTherapeutics
7.4 Kelonia Therapeutics
7.5 EsoBiotec (AstraZeneca)
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The in Vivo CAR-T Therapy market can be segmented based on various criteria, including delivery, indication and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in In Vivo CAR-T Therapy right now, from free public sources.
Clinical trials
32 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the In Vivo CAR-T Therapy market in Asia Pacific?
Placeholder estimate: about $26.2 Mn in 2025, rising to about $1.06 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the In Vivo CAR-T Therapy market in Asia Pacific growing?
Placeholder estimate: about 50.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the In Vivo CAR-T Therapy market report cover?
The report splits the market by delivery (Lentiviral Vectors, Lipid Nanoparticles, Targeted Viral Vectors), indication (Blood Cancers, Autoimmune Diseases, Solid Tumors) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the In Vivo CAR-T Therapy market?
Key players include Capstan Therapeutics (AbbVie), Umoja Biopharma, Interius BioTherapeutics, Kelonia Therapeutics and EsoBiotec (AstraZeneca).
What is driving the In Vivo CAR-T Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the in Vivo CAR-T Therapy market.
How many clinical trials on In Vivo CAR-T Therapy are running in Asia Pacific?
32 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on In Vivo CAR-T Therapy?
PubMed lists 24 papers on In Vivo CAR-T Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.